整理 | GLP1减重宝典内容团队2025年4月29日,阿斯利康在发布2025年第一季度财报时宣布,将正式退出神经科学领域的研发工作,未来将更加专注于减重、免疫学等核心治疗方向。根据当天公布的最新研发管线,公司已终止与Eli Lilly合作开发的阿尔茨海默病抗体候选药物MEDI1814,以及治疗偏头痛的单克隆抗体MEDI0618的项目。目前,阿斯利康在神经科学方向已无在研项目。在电话会议中,...
Source Link整理 | GLP1减重宝典内容团队2025年4月29日,阿斯利康在发布2025年第一季度财报时宣布,将正式退出神经科学领域的研发工作,未来将更加专注于减重、免疫学等核心治疗方向。根据当天公布的最新研发管线,公司已终止与Eli Lilly合作开发的阿尔茨海默病抗体候选药物MEDI1814,以及治疗偏头痛的单克隆抗体MEDI0618的项目。目前,阿斯利康在神经科学方向已无在研项目。在电话会议中,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.